Safety and Immunogenicity of Q Fever Vaccine
NCT02092142
Withdrawn
The purpose of this study is to evaluate the safety of Q Fever Vaccine, Phase I, Inactivated, Dried, NDBR 105 and collect data on incidence of occupational Q fever infection in vaccinated personnel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/30/2019
Locations: Special Immunizations Program, Division of Medicine, USAMRIID, Fort Deterick, Maryland
Conditions: Q Fever
Register for Updates
Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab
NCT03056924
Completed
Patients with Crohn's disease (CD) and ulcerative colitis (UC) are often treated with medications that suppress the immune system. These patients are therefore at increased risk for developing infections, such as influenza, pneumonia, and hepatitis B, which may be prevented by vaccination. While awareness is increasing among gastroenterologists of the importance of vaccinations in the IBD patient, there continues to be some question of the effectiveness of vaccination in immunosuppressed patient... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/27/2019
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: Inflammatory Bowel Diseases
Register for Updates
Booster Dose (50 µg) of Recombinant Ricin Toxin Vaccine (RVEc™) in Previously Vaccinated Healthy Adults
NCT01846104
Completed
The purpose of this study is to evaluate the safety and immunogenicity of a single 50-μg booster dose of RVEc. Subjects will be recruited from the cohort that received three 50-μg doses of RVEc in a Phase 1 trial (NCT01317667).
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
12/17/2019
Locations: Department of Clinical Research, USAMRIID, Frederick, Maryland
Conditions: Ricin Poisoning
Register for Updates
Open-Label Influenza Vaccine Evaluation
NCT02872311
Completed
This is an open-label, randomized trial in up to 210 adults aged 65-74 years to evaluate the immune response to consecutive influenza vaccination across 2 seasons. Participants will be randomized to receive 1 of 3 licensed and recommended vaccines in the first year; 2 arms will receive the same vaccination in the second year and the third arm will be randomized again to 1 of 3 licensed vaccines. All participants will have pre and post-vaccination serum blood draws for a total of 6 draws over 18... Read More
Gender:
ALL
Ages:
Between 65 years and 74 years
Trial Updated:
12/03/2019
Locations: Marshfield Clinic - Marshfield Center, Marshfield, Wisconsin
Conditions: Immune Response
Register for Updates
Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine
NCT02270944
Completed
The purpose of the present study is to assess and compare in healthy non-pregnant women 18 to 40 years of age the safety and immunogenicity of a liquid formulation of Group B Streptococcus (GBS) Trivalent Vaccine (not requiring reconstitution prior to administration), and of the lyophilized formulation of GBS Trivalent Vaccine, administered in non-pregnant and pregnant women in the clinical development program to date.
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
11/19/2019
Locations: GSK Investigational Site, Redding, California +8 locations
Conditions: Infections, Streptococcal, Streptococcal Infections
Register for Updates
Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer
NCT00849121
Completed
The investigators are trying to find new methods to treat prostate cancer. The approach is to try to enhance patients' own immune response against the cancer. In this study, the investigators will be testing the safety of a vaccine that may be able to help the body fight prostate cancer. The vaccine, called pTVG-HP, is a piece of DNA genetic material that contains genetic code for a protein that is made by the prostate gland, called prostatic acid phosphatase (PAP). The vaccine will be given to... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/13/2019
Locations: University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin
Conditions: Prostate Cancer
Register for Updates
Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults
NCT02233816
Completed
A phase II trial multicenter, observer-blind, randomized, dose-ranging, placebo-controlled study to evaluate the immunogenicity, safety, and tolerability of a single intramuscular injection of plant-derived Seasonal VLP Quadrivalent Influenza Vaccine administered to healthy adults 18-49 years of age. A total of three hundred subjects will be randomized in four (4) groups of 75 subjects to receive one injection of either a low, a medium, or a high dose level of the quadrivalent VLP influenza vac... Read More
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
11/11/2019
Locations: Broward Research Group, Hollywood, Florida +1 locations
Conditions: Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Register for Updates
To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid
NCT00617409
Completed
The purpose of this research study is to test a tumor (cancer) vaccine given along with chemotherapy to determine if this vaccine will increase the chances of the tumor shrinking and/or the amount of time that people who have this disease will live.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/06/2019
Locations: H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
Conditions: Small Cell Lung Cancer
Register for Updates
Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults
NCT02831751
Completed
This Phase 2 Quadrivalent VLP Vaccine study is intended to replicate and extend the immunogenicity and safety results obtained in earlier Phase 1-2 and Phase 2 studies. The study is being conducted to evaluate that the immunogenicity profile of the Quadrivalent VLP Vaccine meets the US Center for Biologics Evaluation and Research (CBER) licensure criteria and to evaluate if the immunogenicity and the safety profile of the Quadrivalent VLP Vaccine is acceptable and comparable to that of the FluLa... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
10/23/2019
Locations: Paradigm Research - Redding, Redding, California +14 locations
Conditions: Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Register for Updates
Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine
NCT01024686
Terminated
The purpose of this study is to assess safety and tolerability of escalating doses of a genetically attenuated parasite malaria vaccine (p52-/p36- GAP vaccine) in healthy malaria-naive adults. The study will also assess preliminary efficacy of p52-/p36- GAP vaccine following primary experimental challenge with P. falciparum sporozoites. Lastly, the study will assess immunogenicity of p52-/p36- GAP in malaria-naïve healthy adults and preliminary efficacy of p52-/p36- GAP vaccine following primary... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/04/2019
Locations: Walter Reed Army Institute of Research, Silver Spring, Maryland
Conditions: Malaria
Register for Updates
PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment
NCT00694551
Completed
Pilot Immunotherapy Study of Combination Prostate Specific Membrane Antigen (PSMA) and T-cell receptor γ alternate reading frame protein (TARP) Peptide With Poly IC-LC Adjuvant in Human Leukocyte Antigens (HLA)-A2 (+) Patients With Elevated prostatic specific antigen (PSA) After Initial Definitive Treatment The purpose of the study is to see if the PSMA/TARP proteins in the vaccine, along with the Hiltonol, can arouse and train the immune system to kill the prostate cancer cells. Prostate cance... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/02/2019
Locations: H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida +1 locations
Conditions: Prostate Cancer
Register for Updates
Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients
NCT02461758
Completed
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract which includes Crohn's disease (CD) and ulcerative colitis (UC). A recent epidemiological investigation estimates that nearly 4 million people worldwide are affected and approximately 1.4 million of these cases occur in the United States. IBD can lead to debilitating symptoms, hospitalizations, decreased quality of life, frequent procedures and/or surgery. Treatment options consist of immunosuppress... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
09/18/2019
Locations: University of Wisconsin Hospital & Clinics, Madison, Wisconsin
Conditions: Inflammatory Bowel Disease (IBD)
Register for Updates